IL5 and Increased total eosinophil count: Bronchial biopsies from atopic asthma patients treated with anti-IL-5 (mepolizumab) showed an association between reduced airway eosinophilia and the significant reduction of biomarkers for airway remodeling such as RBM collagen, tenascin, and lumican deposition [62].